FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010219939> ?p ?o ?g. }

• W3010219939 endingPage "234" @default.
• W3010219939 startingPage "228" @default.
• W3010219939 abstract "BackgroundStereotactic body radiation therapy (SBRT) is an accepted primary treatment option for inoperable early-stage non-small cell lung cancer (NSCLC). The role of SBRT in the treatment of operable disease remains unclear. We retrospectively evaluated patients with operable early-stage NSCLC who elected to receive primary SBRT, examined factors associated with SBRT, and compared overall survival after surgical resection and SBRT.MethodsThe National Cancer Database was queried for patients with stage I/II, N0 NSCLC from 2004 to 2016. The proportion of patients who refused recommended surgery and were treated with SBRT was calculated. A propensity score predicting the probability of refusing surgery and receiving SBRT was generated and used to match SBRT and resected patients. Long-term overall survival was compared in the matched cohort using the Kaplan-Meier method and Cox regression.ResultsWe identified 1359 patients (0.98%) who refused recommended surgery and elected SBRT. This proportion increased annually, from 0.1% in 2004 to 1.7% in 2016. Factors associated with SBRT were older age, black race, Medicaid coverage, lower T stage, and more recent diagnosis year. Propensity matching resulted in 1315 well-balanced pairs. Surgery was associated with higher median survival (74 vs 47 months, P < .01) in the matched cohort. Survival benefit persisted after adjusting for covariates on Cox regression (hazard ratio, 1.69; P < .01).ConclusionsMedian survival was significantly higher after surgery compared with SBRT in a risk-adjusted matched cohort of patients judged to be surgical candidates. Operable patients considering primary SBRT should be educated regarding this difference in survival. Stereotactic body radiation therapy (SBRT) is an accepted primary treatment option for inoperable early-stage non-small cell lung cancer (NSCLC). The role of SBRT in the treatment of operable disease remains unclear. We retrospectively evaluated patients with operable early-stage NSCLC who elected to receive primary SBRT, examined factors associated with SBRT, and compared overall survival after surgical resection and SBRT. The National Cancer Database was queried for patients with stage I/II, N0 NSCLC from 2004 to 2016. The proportion of patients who refused recommended surgery and were treated with SBRT was calculated. A propensity score predicting the probability of refusing surgery and receiving SBRT was generated and used to match SBRT and resected patients. Long-term overall survival was compared in the matched cohort using the Kaplan-Meier method and Cox regression. We identified 1359 patients (0.98%) who refused recommended surgery and elected SBRT. This proportion increased annually, from 0.1% in 2004 to 1.7% in 2016. Factors associated with SBRT were older age, black race, Medicaid coverage, lower T stage, and more recent diagnosis year. Propensity matching resulted in 1315 well-balanced pairs. Surgery was associated with higher median survival (74 vs 47 months, P < .01) in the matched cohort. Survival benefit persisted after adjusting for covariates on Cox regression (hazard ratio, 1.69; P < .01). Median survival was significantly higher after surgery compared with SBRT in a risk-adjusted matched cohort of patients judged to be surgical candidates. Operable patients considering primary SBRT should be educated regarding this difference in survival." @default.
• W3010219939 created "2020-03-13" @default.
• W3010219939 creator A5023012457 @default.
• W3010219939 creator A5030759471 @default.
• W3010219939 creator A5033305636 @default.
• W3010219939 creator A5044188819 @default.
• W3010219939 creator A5059482045 @default.
• W3010219939 creator A5077440726 @default.
• W3010219939 date "2020-07-01" @default.
• W3010219939 modified "2023-10-03" @default.
• W3010219939 title "Survival of Primary Stereotactic Body Radiation Therapy Compared With Surgery for Operable Stage I/II Non-small Cell Lung Cancer" @default.
• W3010219939 cites W1862025790 @default.
• W3010219939 cites W1880287467 @default.
• W3010219939 cites W1984747135 @default.
• W3010219939 cites W1991725363 @default.
• W3010219939 cites W2004079062 @default.
• W3010219939 cites W2036193982 @default.
• W3010219939 cites W2046793046 @default.
• W3010219939 cites W2093132244 @default.
• W3010219939 cites W2098354451 @default.
• W3010219939 cites W2100067358 @default.
• W3010219939 cites W2106893486 @default.
• W3010219939 cites W2107814019 @default.
• W3010219939 cites W2115646671 @default.
• W3010219939 cites W2126049444 @default.
• W3010219939 cites W2134118294 @default.
• W3010219939 cites W2285619954 @default.
• W3010219939 cites W2531702976 @default.
• W3010219939 cites W2762168933 @default.
• W3010219939 cites W2771452691 @default.
• W3010219939 cites W2784067092 @default.
• W3010219939 cites W2891445272 @default.
• W3010219939 cites W2921870800 @default.
• W3010219939 cites W2948365399 @default.
• W3010219939 cites W2971714325 @default.
• W3010219939 doi "https://doi.org/10.1016/j.athoracsur.2020.01.073" @default.
• W3010219939 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7405040" @default.
• W3010219939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32147416" @default.
• W3010219939 hasPublicationYear "2020" @default.
• W3010219939 type Work @default.
• W3010219939 sameAs 3010219939 @default.
• W3010219939 citedByCount "26" @default.
• W3010219939 countsByYear W30102199392020 @default.
• W3010219939 countsByYear W30102199392021 @default.
• W3010219939 countsByYear W30102199392022 @default.
• W3010219939 countsByYear W30102199392023 @default.
• W3010219939 crossrefType "journal-article" @default.
• W3010219939 hasAuthorship W3010219939A5023012457 @default.
• W3010219939 hasAuthorship W3010219939A5030759471 @default.
• W3010219939 hasAuthorship W3010219939A5033305636 @default.
• W3010219939 hasAuthorship W3010219939A5044188819 @default.
• W3010219939 hasAuthorship W3010219939A5059482045 @default.
• W3010219939 hasAuthorship W3010219939A5077440726 @default.
• W3010219939 hasBestOaLocation W30102199392 @default.
• W3010219939 hasConcept C10515644 @default.
• W3010219939 hasConcept C126322002 @default.
• W3010219939 hasConcept C126838900 @default.
• W3010219939 hasConcept C141071460 @default.
• W3010219939 hasConcept C146357865 @default.
• W3010219939 hasConcept C151730666 @default.
• W3010219939 hasConcept C167135981 @default.
• W3010219939 hasConcept C17923572 @default.
• W3010219939 hasConcept C207103383 @default.
• W3010219939 hasConcept C2776256026 @default.
• W3010219939 hasConcept C2777589429 @default.
• W3010219939 hasConcept C44249647 @default.
• W3010219939 hasConcept C50382708 @default.
• W3010219939 hasConcept C509974204 @default.
• W3010219939 hasConcept C71924100 @default.
• W3010219939 hasConcept C72563966 @default.
• W3010219939 hasConcept C86803240 @default.
• W3010219939 hasConceptScore W3010219939C10515644 @default.
• W3010219939 hasConceptScore W3010219939C126322002 @default.
• W3010219939 hasConceptScore W3010219939C126838900 @default.
• W3010219939 hasConceptScore W3010219939C141071460 @default.
• W3010219939 hasConceptScore W3010219939C146357865 @default.
• W3010219939 hasConceptScore W3010219939C151730666 @default.
• W3010219939 hasConceptScore W3010219939C167135981 @default.
• W3010219939 hasConceptScore W3010219939C17923572 @default.
• W3010219939 hasConceptScore W3010219939C207103383 @default.
• W3010219939 hasConceptScore W3010219939C2776256026 @default.
• W3010219939 hasConceptScore W3010219939C2777589429 @default.
• W3010219939 hasConceptScore W3010219939C44249647 @default.
• W3010219939 hasConceptScore W3010219939C50382708 @default.
• W3010219939 hasConceptScore W3010219939C509974204 @default.
• W3010219939 hasConceptScore W3010219939C71924100 @default.
• W3010219939 hasConceptScore W3010219939C72563966 @default.
• W3010219939 hasConceptScore W3010219939C86803240 @default.
• W3010219939 hasFunder F4320332161 @default.
• W3010219939 hasFunder F4320337338 @default.
• W3010219939 hasFunder F4320337351 @default.
• W3010219939 hasIssue "1" @default.
• W3010219939 hasLocation W30102199391 @default.
• W3010219939 hasLocation W30102199392 @default.
• W3010219939 hasOpenAccess W3010219939 @default.
• W3010219939 hasPrimaryLocation W30102199391 @default.
• W3010219939 hasRelatedWork W1989251301 @default.
• W3010219939 hasRelatedWork W1997539222 @default.

• next